{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T14:11:26Z","timestamp":1762179086061,"version":"build-2065373602"},"reference-count":14,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,6,15]],"date-time":"2016-06-15T00:00:00Z","timestamp":1465948800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013671","name":"Sun Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013671","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Heart Journal"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.ihj.2016.09.002","type":"journal-article","created":{"date-parts":[[2016,9,21]],"date-time":"2016-09-21T23:06:30Z","timestamp":1474499190000},"page":"766-771","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy and safety of the intensive dose of rosuvastatin 40 mg\/day in patients with acute coronary syndrome and at high risk of cardiovascular disease-ROSUVEES-2"],"prefix":"10.1016","volume":"68","author":[{"given":"Chetan P.","family":"Shah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhaskar P.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameer I.","family":"Dani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.B.","family":"Channa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.S.","family":"Lakshmanan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.C.","family":"Krishnamani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashwani","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Moorthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2015","series-title":"Acute Coronary Syndromes (ACS) (Unstable Angina; Acute MI; Myocardial Infarction)","author":"Warnica","key":"10.1016\/j.ihj.2016.09.002_bib0075"},{"key":"10.1016\/j.ihj.2016.09.002_bib0080","first-page":"227","article-title":"Statins as first-line therapy for acute coronary syndrome?","volume":"17","author":"Ostadal","year":"2012","journal-title":"Exp Clin Cardiol"},{"key":"10.1016\/j.ihj.2016.09.002_bib0085","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2147\/VHRM.S3662","article-title":"Efficacy and safety of rosuvastatin in the management of dyslipidemia","volume":"5","author":"Rubba","year":"2009","journal-title":"Vasc Health Risk Manage"},{"issue":"suppl A","key":"10.1016\/j.ihj.2016.09.002_bib0090","doi-asserted-by":"crossref","first-page":"A32","DOI":"10.1016\/j.ehjsup.2004.01.008","article-title":"Do statins play a role in the early management of the acute coronary syndrome?","volume":"6","author":"Sacks","year":"2004","journal-title":"Eur Heart J Suppl"},{"key":"10.1016\/j.ihj.2016.09.002_bib0095","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2147\/VHRM.S1653","article-title":"Clinical efficacy and safety of statins in managing cardiovascular risk","volume":"4","author":"Kapur","year":"2008","journal-title":"Vasc Health Risk Manage"},{"key":"10.1016\/j.ihj.2016.09.002_bib0100","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1161\/01.CIR.0000012530.68333.C8","article-title":"Withdrawal of statins increases event rates in patients with acute coronary syndromes","volume":"105","author":"Heeschen","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2016.09.002_bib0105","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2016.09.002_bib0110","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.jacc.2007.11.075","article-title":"Lipid levels after acute coronary syndromes","volume":"51","author":"Pitt","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ihj.2016.09.002_bib0115","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1001\/archinte.166.17.1814","article-title":"The effect of early, intensive statin therapy on acute coronary syndrome: a meta-analysis of randomized controlled trials","volume":"166","author":"Hulten","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ihj.2016.09.002_bib0120","first-page":"41","article-title":"Rosuvastatin: role in cardiovascular high-risk patient","volume":"61","author":"Feliciano-Alfonso","year":"2013","journal-title":"Rev Fac Med"},{"key":"10.1016\/j.ihj.2016.09.002_bib0125","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1110874","article-title":"Effect of two intensive statin regimens on progression of coronary disease","volume":"365","author":"Nicholls","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ihj.2016.09.002_bib0130","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.acvd.2008.05.010","article-title":"Effects of rosuvastatin and atorvastatin on the apolipoprotein B\/apolipoprotein A-1 ratio in patients with an acute coronary syndrome: the CENTAURUS trial design","volume":"101","author":"Lablanche","year":"2008","journal-title":"Arch Cardiovasc Dis"},{"issue":"suppl","key":"10.1016\/j.ihj.2016.09.002_bib0135","doi-asserted-by":"crossref","first-page":"23K","DOI":"10.1016\/S0002-9149(03)00779-3","article-title":"Benefit-risk assessment of rosuvastatin 10 to 40 milligrams","volume":"92","author":"Brewer","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ihj.2016.09.002_bib0140","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.amjcard.2011.12.015","article-title":"Comparison of lipid-modifying efficacy of rosuvastatin versus atorvastatin in patients with acute coronary syndrome (from the LUNAR study)","volume":"109","author":"Pitt","year":"2012","journal-title":"Am J Cardiol"}],"container-title":["Indian Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001948321630219X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001948321630219X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T13:23:04Z","timestamp":1762176184000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001948321630219X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S001948321630219X"],"URL":"https:\/\/doi.org\/10.1016\/j.ihj.2016.09.002","relation":{},"ISSN":["0019-4832"],"issn-type":[{"type":"print","value":"0019-4832"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of the intensive dose of rosuvastatin 40mg\/day in patients with acute coronary syndrome and at high risk of cardiovascular disease-ROSUVEES-2","name":"articletitle","label":"Article Title"},{"value":"Indian Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ihj.2016.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier B.V. on behalf of Cardiological Society of India.","name":"copyright","label":"Copyright"}]}}